These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32420079)

  • 21. Sintilimab-induced autoimmune diabetes: A case report and review of the literature.
    Yang J; Wang Y; Tong XM
    World J Clin Cases; 2022 Feb; 10(4):1263-1277. PubMed ID: 35211559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Programmed Cell Death-1 Monoclonal Antibody Therapy and Type 1 Diabetes Mellitus: A Review of the Literature.
    Farina KA; Kane MP
    J Pharm Pract; 2021 Feb; 34(1):133-140. PubMed ID: 31269868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy.
    Lee S; Morgan A; Shah S; Ebeling PR
    Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29732161
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy.
    Alrifai T; Ali FS; Saleem S; Ruiz DCM; Rifai D; Younas S; Qureshi F
    Case Rep Oncol Med; 2019; 2019():8781347. PubMed ID: 31781446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management.
    Kapke J; Shaheen Z; Kilari D; Knudson P; Wong S
    Case Rep Oncol; 2017; 10(3):897-909. PubMed ID: 29279690
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies.
    Way J; Drakaki A; Drexler A; Freeby M
    BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28978581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients.
    Saruwatari K; Sato R; Nakane S; Sakata S; Takamatsu K; Jodai T; Mito R; Horio Y; Saeki S; Tomita Y; Sakagami T
    Cancers (Basel); 2019 Jan; 11(2):. PubMed ID: 30682845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti‑PD‑1 immune checkpoint inhibitor inducing endocrine toxicity in a patient with advanced lung cancer: A case report and literature review.
    Bao S; Jiang X
    Exp Ther Med; 2022 Nov; 24(5):681. PubMed ID: 36185768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperosmolar Hyperglycaemic State and Diabetic Ketoacidosis in Nivolumab-Induced Insulin-Dependent Diabetes Mellitus.
    Saleh AO; Taha R; Mohamed SFA; Bashir M
    Eur J Case Rep Intern Med; 2021; 8(8):002756. PubMed ID: 34527623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.
    Hickmott L; De La Peña H; Turner H; Ahmed F; Protheroe A; Grossman A; Gupta A
    Target Oncol; 2017 Apr; 12(2):235-241. PubMed ID: 28255845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma.
    Aleksova J; Lau PK; Soldatos G; McArthur G
    BMJ Case Rep; 2016 Nov; 2016():. PubMed ID: 27881588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid onset type 1 diabetes with anti-PD-1 directed therapy.
    Yun K; Daniels G; Gold K; Mccowen K; Patel SP
    Oncotarget; 2020 Jul; 11(28):2740-2746. PubMed ID: 32733645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies.
    Fujita K; Uchida N; Yamamoto Y; Kanai O; Okamura M; Nakatani K; Sawai S; Mio T
    Anticancer Res; 2019 Jul; 39(7):3917-3921. PubMed ID: 31262921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uveal Effusion After Immune Checkpoint Inhibitor Therapy.
    Thomas M; Armenti ST; Ayres MB; Demirci H
    JAMA Ophthalmol; 2018 May; 136(5):553-556. PubMed ID: 29677240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-PD-L1 Treatment Induced Central Diabetes Insipidus.
    Zhao C; Tella SH; Del Rivero J; Kommalapati A; Ebenuwa I; Gulley J; Strauss J; Brownell I
    J Clin Endocrinol Metab; 2018 Feb; 103(2):365-369. PubMed ID: 29220526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Case Report of Graves' Disease Induced by the Anti-Human Programmed Cell Death-1 Monoclonal Antibody Pembrolizumab in a Bladder Cancer Patient.
    Yajima K; Akise Y
    Case Rep Endocrinol; 2019; 2019():2314032. PubMed ID: 31772785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis.
    Avram AM; Patel V; Taylor HC; Kirwan JP; Kalhan S
    Ann Pharmacother; 2001 Nov; 35(11):1381-7. PubMed ID: 11724088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports.
    Polcwiartek C; Vang T; Bruhn CH; Hashemi N; Rosenzweig M; Nielsen J
    Psychopharmacology (Berl); 2016 Oct; 233(21-22):3663-3672. PubMed ID: 27592232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.